REMD Biotherapeutics Announces Dosing of First Type 1 Diabetes Patient with REMD-477, a Glucagon Receptor Monoclonal Antibody

Biotech Investing

REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd (“CoSci-REMD Bio”), today announced that the first patient with type 1 diabetes was dosed with REMD-477 on their phase 1b clinical study in the United States. The randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, phyarmacodynamics, and glucose and …

REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing CoSci-REMD Bio Med-Tech Co, Ltd (“CoSci-REMD Bio”), today announced that the first patient with type 1 diabetes was dosed with REMD-477 on their phase 1b clinical study in the United States. The randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, phyarmacodynamics, and glucose and insulin dose-lowering properties of REMD-477 in up to 20 patients with type 1 diabetes administered a single subcutaneous injection will enroll at Washington University School of Medicine in St. Louis and at U.C. San Diego (UCSD) School of Medicine.
According Robert R. Henry, M.D., Professor of Medicine at UCSD, Chief of the Center for Metabolic Research at the Veterans Affairs Healthcare System in San Diego:

While insulin is a primary treatment for type 1 diabetes, exogenous insulin treatment may not be completely effective at controlling the disease, and hypoglycemia is a major and sometimes life-threatening side effect of insulin therapy, and a daily fact of life, for people with this disease. An additive therapy that can reduce daily insulin doses and reduce hyperglycemia may substantially reduce complications, and improve diabetic control and quality of life for type 1 diabetic patients.

Click here to view the news. 

The Conversation (0)
×